The Scientist Logo_white
ARTICLE

Gaining Control Over Clinical Trial Design

Researchers leverage big data to generate external control groups and accelerate clinical trials.


Medidata logo

 

Information you provide will be shared with the sponsors for this content. The Scientist or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.

Discover how external control groups benefit clinical trials

Randomized controlled trials are the gold standard for evaluating the safety and efficacy of new therapeutics, but researchers often struggle to recruit sufficient patients to complete their studies, especially when treating rare diseases. External control groups that are compiled with existing patient data from previously conducted clinical trials can replace a study’s traditional control group. Because external control groups must be properly designed, researchers combine cutting-edge technologies, including artificial intelligence (AI) and data analytics, to assess large patient datasets.

Download this article from Medidata to learn

  • How researchers integrate AI and data analytics to enhance clinical trials
  • The benefits of external control arms
  • How to design hybrid clinical trials by combining internal and external control groups